Metabolically Healthy Child Obesity Still Raises Cardiometabolic Risk
March 28, 2026 / Childhood obesity / Cardiometabolic risk / Type 2 diabetes / Hypertension / Pediatric health
Childhood metabolically healthy obesity is associated with increased long-term risk of type 2 diabetes, hypertension, and dyslipidemia. Findings emphasize early intervention and weight management to reduce future cardiometabolic disease risk, regardless of initial metabolic status.
Do GLP-1 Drugs Reduce Cancer Risk or Increase It?
March 29, 2026 / GLP-1 drugs / Cancer risk / Obesity treatment / Type 2 diabetes / Metabolic health
GLP-1 receptor agonists improve metabolic function and may reduce obesity-related cancer risk through weight loss and anti-inflammatory effects, though causal evidence remains unconfirmed. Further research is needed to clarify their long-term impact on cancer incidence.
Vida Health Redefines Metabolic Care with New Control Framework for Whole-Population Management
March 27, 2026 / Metabolic health / Population health / Cardiometabolic disease / Chronic disease management / Digital health
Vida Health’s Metabolic Control Framework integrates clinical, behavioral, and mental health data to optimize management of cardiometabolic diseases. This population health approach enables personalized care pathways, improving outcomes and reducing progression of conditions like diabetes, obesity, and hypertension.
Scientists discover a hidden system that turns brown fat into a calorie burner
March 28, 2026 / Brown fat / Thermogenesis / Obesity research / Metabolic disease / Energy metabolism
Discovery of the SLIT3 pathway reveals how brown adipose tissue develops vascular and neural networks to enhance thermogenesis. This mechanism may inform novel treatments targeting obesity and metabolic disorders by increasing energy expenditure.
Insulin Resistance Detected Early May Guide Hidradenitis Suppurativa Therapy
March 28, 2026 / Hidradenitis suppurativa / Insulin resistance / Inflammatory disease / Metabolic dysfunction / Dermatology
Early detection of insulin resistance using HOMA-IR in hidradenitis suppurativa may guide targeted treatment strategies, addressing metabolic dysfunction and inflammation to improve disease outcomes and tissue healing.
Eating more dairy and calcium may lower metabolic syndrome odds
March 25, 2026 / Metabolic syndrome / Dairy intake / Calcium nutrition / Insulin resistance / Cardiometabolic health
Higher dietary calcium and dairy intake may be associated with reduced risk of metabolic syndrome, potentially improving insulin sensitivity, lipid profiles, and blood pressure, though variability across studies highlights the need for further clinical validation.
Wholegrain rye changes gut bacteria and lowers inflammation in obesity trial
March 24, 2026 / Gut microbiome / Whole grains / Obesity / Inflammation / Metabolic health
Wholegrain rye consumption improved gut microbiota composition and reduced systemic inflammation in obese individuals, despite similar weight loss to refined wheat diets. Findings highlight microbiome-mediated metabolic benefits, particularly for those with insulin resistance.
Why Women with Metabolic Risk Factors Face Higher Odds of Liver Fibrosis
March 25, 2026 / Liver fibrosis / Metabolic syndrome / Women’s health / Insulin resistance / Liver disease
Women with metabolic risk factors such as diabetes and central obesity have a higher likelihood of developing liver fibrosis, potentially driven by hormonal changes, insulin resistance, and inflammation, underscoring the need for early screening and targeted prevention.
New algorithm enables precise subtyping of metabolic liver disease
March 26, 2026 / Metabolic liver disease / MASLD / Precision medicine / Risk stratification / Liver fibrosis
A novel algorithm enables precise subtyping of metabolic-associated steatotic liver disease (MASLD) using key clinical markers, supporting personalized risk stratification and management of liver and related cardiometabolic complications.
Treatment Breakthroughs for Metabolic Dysfunction-Associated Steatohepatitis
March 25, 2026 / MASH treatment / Fatty liver disease / GLP-1 therapy / Liver fibrosis / Metabolic syndrome
Emerging therapies for MASH, including GLP-1 receptor agonists and thyroid hormone receptor-β modulators, offer disease-modifying potential by reducing liver fat, inflammation, and fibrosis, expanding treatment beyond lifestyle interventions for metabolic liver disease.
New Advances in Diabetes Drugs Are Transforming Treatment of Liver Disease
March 29, 2026 / MASLD treatment / Diabetes drugs / GLP-1 therapy / Liver disease / Metabolic dysfunction
Diabetes therapies, including GLP-1 and other metabolic agents, are reshaping MASLD treatment by targeting underlying metabolic dysfunction, offering potential to improve liver outcomes and redefine management of fatty liver disease.
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
March 31, 2026 / Polycystic kidney disease / AMPK activation / Kidney disease / Clinical trials / Metabolic therapy
PXL770, an AMPK activator, targets underlying mechanisms of autosomal dominant polycystic kidney disease by reducing cyst growth and progression. Upcoming clinical trials will evaluate its efficacy as a novel metabolic-based therapeutic approach.
Fearing liver cancer when you’re living with fatty liver disease
March 31, 2026 / Fatty liver disease / MASH / Liver cancer risk / Chronic liver disease / Hepatic fibrosis
Metabolic dysfunction–associated steatohepatitis (MASH) can progress from fatty liver to cirrhosis and liver cancer if untreated, highlighting the importance of early diagnosis, monitoring, and intervention to reduce long-term hepatic complications.
How gut imbalance may drive obesity, diabetes, and heart disease
March 30, 2026 / Gut microbiome / Metabolic disease / Insulin resistance / Inflammation / Cardiovascular health
Gut microbiome imbalance contributes to obesity, diabetes, and cardiovascular disease through inflammation, insulin resistance, and impaired gut barrier function. Dysbiosis-driven metabolic pathways highlight potential for microbiome-targeted therapies to improve cardiometabolic health.
Tirzepatide Boosts Metabolic Health in Partial Lipodystrophy
March 31, 2025 / Tirzepatide / Lipodystrophy / Metabolic health / GLP-1 therapy / Insulin resistance
Tirzepatide significantly improves metabolic parameters in partial lipodystrophy, reducing body weight, HbA1c, triglycerides, liver enzymes, and insulin requirements, indicating potential as a targeted therapy for severe metabolic dysfunction.
Pancreatic fat linked to greater heart and metabolic health risks in children and adolescents with obesity
March 31, 2026 / Pancreatic fat / Childhood obesity / Cardiometabolic risk / Insulin resistance / Pediatric health
Elevated pancreatic fat in youth with obesity is associated with increased cardiometabolic risk, including hypertension, insulin resistance, and visceral adiposity, highlighting its potential as an early biomarker for targeted intervention and prevention of metabolic disease.
Multi-task deep learning identifies four MASLD subtypes for precision cardiovascular– liver–kidney–metabolic management
March 26, 2026 / MASLD subtypes / Precision medicine / Cardiometabolic risk / Liver disease / Deep learning
A deep learning algorithm identified four MASLD subtypes with distinct cardiovascular, liver, kidney, and metabolic risks, enabling precision risk stratification and targeted interventions to improve outcomes across multisystem disease complications.
Pune-based iThrive reveals thesis on root-cause strategy for reversing Type 2 diabetes
March 31, 2026 / Type 2 diabetes / Insulin resistance / Metabolic health / Diabetes remission / Lifestyle intervention
Emerging evidence suggests type 2 diabetes may be reversible through targeted interventions addressing insulin resistance, liver and pancreatic fat, and metabolic dysfunction, with lifestyle, nutrition, and weight loss playing key roles in improving glucose regulation.
Switching from Dulaglutide to Tirzepatide Enhances Patient-Reported Well-Being in Type 2 Diabetes
March 30, 2025 / Type 2 diabetes / Tirzepatide / GLP-1 therapy / Patient outcomes / Metabolic health
Switching from dulaglutide to tirzepatide improves glycemic control, weight outcomes, and patient-reported emotional well-being in type 2 diabetes, highlighting benefits of dual GIP/GLP-1 therapy in comprehensive metabolic and quality-of-life management.